Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer;Toxicité cutanée grave après Pemetrexed en traitement de deuxième ligne pour un cancer bronchique

Revue des Maladies Respiratoires

Volumn 24, Issue 5, 2007, Pages 635-638

  Tummino, C ^a   Barlesi, F ^a   Tchouhadjian, C ^a   Tasei, A M ^a   Gaudy Marqueste, C ^a   Richard, M A ^a   Astoul, P ^a  

^a HÔPITAL SAINTE MARGUERITE   (France)

Author keywords

Drug monitoring; Gamma globulins; Lyell's syndrome; Non small cell lung cancer; Pemetrexed; Toxic epidermal necrolysis

Indexed keywords

IMMUNOGLOBULIN; NAVELBINE; PEMETREXED; STEROID;

AGED; ARTICLE; BLISTER; CASE REPORT; DESQUAMATION; DETERIORATION; DISEASE SEVERITY; DRUG SAFETY; ERYTHEMA; FOLLOW UP; HUMAN; LUNG NON SMALL CELL CANCER; MALE; MULTIPLE CYCLE TREATMENT; PANCYTOPENIA; RHABDOMYOLYSIS; SKIN MANIFESTATION; STEROID THERAPY; TOXIC EPIDERMAL NECROLYSIS; TREATMENT OUTCOME;

EID: 34249702943     PISSN: 07618425     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0761-8425(07)91133-X     Document Type: Article

References (12)

1. National Cancer Institute. Common Terminolgy Criteria for adverse events. December 12, 2003, téléchargé sur http : //www.cancer.gov/.
2. Hanna N, Shepherd F, Fosella F, Pereira J, De Marinis F, Von Pawel J, Gatzemeier U, Chang Yao Tsao T, Pless M, Muller T, Lim H, Desch C, Szondy K, Gervais R, Shaharyar, Manegold C, Paul S, Paoletti P, Einhorn L, Bunn P : Randomized phase III trial of pemetrexed versus docetaxel in patients with non small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004 ; 22 : 1589-97.
3. Vogelzang N, Rusthoven J, Symanowski J, Denham C, Kaukel E, Ruffie P, Gatzemeier U, Boyer M, Emri S, Manegold C, Niyikiza C, Paoletti P : Phase III study of pemetrexed in combination with cisplatin versus alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003 ; 21 : 2636-44.
4. Rhuthoven J, Eisenhauer E, Butts C, Gregg R, Dancey J, Fisher B, Iglesias J : Mutitargeted antifolate LY231514 as first line chemotherapy for patients with advanced non small cell lung cancer: a phase II study. J Clin Oncol 1999 ; 17 : 1194-9.
5. Hureaux J, Le Guen Y, Tuchais C, Savary L, Urban T: Radiation recall dermatitis with pemetrexed. Lung Cancer 2005 ; 50 : 255-8.
6. Barlési F, Tummino C, Tasei AM, Astoul P : Unsuccessful rechallenge with pemetrexed after a previous radiation recall dermatitis. Lung Cancer 2006 ; 54 : 423-5.
7. Mermershtain W, Cohen AD, Lazarev I, Grunwald M, Ariad S : Toxic epidermal necrolysis associated with gemcitabine therapy in a patient with metastatic transitional cell carcinoma of the bladder. J Chemother 2003 ; 15 : 510-1.
8. Werchniak AE, Chaffee S, Dinulos JG : Methotrexate induced bullous acral erythema in a child. J Am Acad Dermatol 2005 ; 52 : S93-5.
9. Paquet P, Pierard GE, Quatresooz P : Novel treatments for drug induced toxic epidermal necrolysis (Lyell's syndrome). Int Arch Allergy Immunol 2005 ; 136 : 205-16.
10. Mahe E, Descamps V : Anti-TNF alpha in dermatology. Ann Dermatol Venereol 2002 ; 129 : 1374-9.
11. Spornraft-Ragaller P, Theilen H, Gottschlich GS, Ragaller M : Treatment of toxic epidermal necrolysis experience with 9 patients with consideration of intraveinous immunoglobulin. Hautarzt 2006 ; 57 : 185-94.
12. French LE, Trent JT, Kerdel FA : Use of intraveinous immunoglobulin in toxic epidermal necrolysis and Stevens-Johnson syndrome: our current understanding. Int Immunopharmacol 2006 ; 6 : 543-9.